RARE241018C55000
- 2.17
- +0.30+16.04%
Ultragenyx Pharmaceutical Newsroom
BofA Securities Maintains Ultragenyx Pharmaceutical(RARE.US) With Buy Rating, Raises Target Price to $83
BofA Securities Maintains Ultragenyx Pharmaceutical(RARE.US) With Buy Rating, Maintains Target Price $73
Leerink Partners Maintains Ultragenyx Pharmaceutical(RARE.US) With Buy Rating, Maintains Target Price $85
Stifel Maintains Ultragenyx Pharmaceutical(RARE.US) With Buy Rating, Maintains Target Price $127
BofA Securities Maintains Ultragenyx Pharmaceutical(RARE.US) With Buy Rating, Announces Target Price $73
TD Cowen Maintains Ultragenyx Pharmaceutical(RARE.US) With Buy Rating, Maintains Target Price $61
Barclays Maintains Ultragenyx Pharmaceutical(RARE.US) With Buy Rating, Maintains Target Price $81
RBC Capital Maintains Ultragenyx Pharmaceutical(RARE.US) With Buy Rating, Maintains Target Price $77
Ultragenyx Pharmaceutical Analyst Ratings
Cantor Fitzgerald Reiterates Overweight on Ultragenyx Pharmaceutical, Maintains $116 Price Target
BofA Securities Maintains Ultragenyx Pharmaceutical(RARE.US) With Buy Rating
Stifel Nicolaus Keeps Their Buy Rating on Ultragenyx Pharmaceutical (RARE)
Stifel Maintains Ultragenyx Pharmaceutical(RARE.US) With Buy Rating, Maintains Target Price $127
Ultragenyx Pharmaceutical Analyst Ratings
Barclays Maintains Overweight on Ultragenyx Pharmaceutical, Lowers Price Target to $81
Truist Financial Maintains Ultragenyx Pharmaceutical(RARE.US) With Buy Rating
Barclays Maintains Ultragenyx Pharmaceutical(RARE.US) With Buy Rating, Maintains Target Price $81
Ultragenyx Pharmaceutical (RARE) Receives a Buy From Barclays
A Quick Look at Today's Ratings for Ultragenyx Pharmaceutical(RARE.US), With a Forecast Between $67 to $127
Ultragenyx Pharma Price Target Raised to $75.00/Share From $72.00 by Wells Fargo